In summary, our findings illustrate that PGRN exerts a previously unrecognized role in Hcy-induced endothelial injury, which is achieved through the interaction of EphA2 signaling, implying that it is a prognostic marker or a promising therapeutic target for cardiovascular disease. This evidence concerns the gene EPHA2 and cardiovascular disorder.